<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01429701</url>
  </required_header>
  <id_info>
    <org_study_id>PREEMS0711</org_study_id>
    <nct_id>NCT01429701</nct_id>
  </id_info>
  <brief_title>Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol in Acute and Sub-acute Dermatitis Eczematous</brief_title>
  <official_title>Unicentric Comparing Effectiveness of Polymyxin B Sulphate + Prednisolone + Benzocaine + Clioquinol to Betamethasone + Gentamicin + Tolnaftate + Clioquinol in Acute and Sub-acute Dermatitis Eczematous</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dermatitis eczematous is a recurrent pruritic skin disorder which has a significant morbidity
      and impaired quality of life due specially pruritus and physical visible skin lesions. The
      purpose of this trial is evaluate the effectiveness of two different topic associations of
      drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

        -  Experiment duration: 22 days

        -  2 visits (days 0,7,15 and 22)

        -  Reducing eczema area and severity index evaluation

        -  Adverse events evaluation

        -  Double blinded, non-inferiority, prospective parallel-group, intend to treat trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction / improvement of signs and symptoms</measure>
    <time_frame>DAY 22</time_frame>
    <description>The reduction of signs and symptoms will be evaluated by OSAAD index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Evaluation</measure>
    <time_frame>DAY 22</time_frame>
    <description>Adverse events will be collected and followed in order to evaluate safety and tolerability.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>Test association cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>polymyxin B sulphate + prednisolone + benzocaine + clioquinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparative association cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>betamethasone + gentamicin + tolnaftato + clioquinol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polymyxin B sulphate + prednisolone + benzocaine + clioquinol</intervention_name>
    <description>applied 3 times / day at lesion</description>
    <arm_group_label>Test association cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betamethasone + gentamicin + tolnaftato + cleoquinol</intervention_name>
    <description>applied 3 times / day at lesion</description>
    <arm_group_label>Comparative association cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be able to understand the study procedures agree to participate and give
             written consent.

          2. Patients with acute or subacute dermatitis with a minimum of 3 symptoms.

        Exclusion Criteria:

          1. Pregnancy or risk of pregnancy.

          2. Lactation

          3. Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study).

          4. Sunlight over exposure in the last 15 days.

          5. Any pathology or past medical condition that can interfere with this protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flávia Addór, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicin Instituto da Pele</affiliation>
  </overall_official>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2011</study_first_submitted>
  <study_first_submitted_qc>September 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2011</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatitis</keyword>
  <keyword>Dermatitis, Atopic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Betamethasone benzoate</mesh_term>
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone Valerate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Polymyxins</mesh_term>
    <mesh_term>Polymyxin B</mesh_term>
    <mesh_term>Tolnaftate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

